ArticleCureus2026
Seventeen-Year Clinical Analysis of Acute Primary Angle-Closure Glaucoma at a Single Japanese Tertiary Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute primary angle-closure glaucoma (APAC) is a sight-threatening emergency that requires immediate intervention; however, there are few reports regarding its therapeutic efficacy and complications. We analyzed 17-year clinical characteristics, surgical outcomes, intraocular pressure (IOP) trajectories, visual acuity (VA), and complications in APAC at a Japanese tertiary center. STUDY
designThis is a retrospective, single-center, observational cohort study.
methodsRecords of 210 patients (229 eyes) with APAC between June 2009 and September 2025 were reviewed. Demographics, presenting IOP, biometric parameters, surgical procedure, VA, and postoperative complications were evaluated. IOP at baseline, postoperative day 1 (POD1), one week, one month, and three months was compared using the Wilcoxon signed-rank test with Bonferroni correction. Onset distribution was assessed using chi-square goodness-of-fit tests.
resultsMean age was 73.2 ± 10.0 years; 68.6% were female. Mean presenting IOP was 53.2 ± 15.4 mmHg. Initial phacoemulsification with intraocular lens implantation (PEA+IOL) was completed in 93.0% of cases. IOP decreased to 16.1 ± 9.9, 15.1 ± 7.3, 14.2 ± 4.7, and 13.9 ± 3.4 mmHg at POD1, one week, one month, and three months, respectively (all corrected p < 0.001). Mean logMAR VA improved from 1.26 ± 0.99 to 0.31 ± 0.87. Paralytic mydriasis occurred in 43.2%, and 26.6% required additional glaucoma treatment. Onset showed no significant deviation from uniform distribution monthly (p = 0.095) or seasonally (p = 0.895).
conclusionInitial PEA+IOL produced sustained IOP reduction and improved VA in Japanese patients with APAC. APAC onset was evenly distributed throughout the year. The high rates of paralytic mydriasis and additional treatment in more than one-quarter of eyes highlight the importance of long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.